Foregut & GERD Surgeon | Houston Heartburn and Reflux Center
15+ years in practice
Published: November 2026 | Last Reviewed: November 2026
RefluxStop™ received FDA approval in August 2026. It had been used in Europe for about eight years before that. Patients from The Woodlands to Sugar Land are starting to ask me about it. Some have read that it is replacing LINX™. Before anyone chooses it, one question deserves an honest answer. Is the device the treatment, or is the operation around it doing the work?
What the Manufacturer Says
Implantica, the company behind RefluxStop™, describes a device that restores the natural anatomy of the gastroesophageal junction. It is designed to keep the lower esophageal sphincter (LES) in the abdomen. It is also meant to preserve the angle of His. That is the angle between the esophagus and the stomach where the esophagus joins the stomach. The company stresses that the device does not encircle the esophagus or press on the food passageway. The message is that this approach keeps the risk of dysphagia minimal.
That description covers anatomy only. It says little about how the operation changes the way the junction behaves. In my view, the manufacturer has not described the mechanism of action well.
What the RefluxStop™ Procedure Actually Involves
The surgical papers tell a more complete story than the marketing does. In the main European study, surgeons first brought about 5 cm of the esophagus into the abdomen. They then freed the back of the fundus up to the angle of His. Next, they sewed the fundus to the front of the esophagus, covering 90 to 110 degrees of its circumference.
That step has a name in reflux surgery. It is an anterior partial fundoplication.
Only then is the silicone device placed. It is about 2.5 cm across. The surgeon folds a pouch of the remaining fundus around it. It hangs like a teardrop inside the stomach. The hiatus is closed more loosely than it would be for a Nissen.
Put simply, RefluxStop™ is a partial fundoplication reinforced by a silicone ball. A Nissen uses the fundus to create a full 360-degree wrap. RefluxStop™ uses only part of the fundus for the wrap. It leaves a good portion free to invaginate the ball.
The Comparison No One Has Made
Partial fundoplication is not new. It has been studied for decades, including in randomized trials against the Nissen. In two Australian trials, an anterior 90-degree partial fundoplication caused less dysphagia than a Nissen. Over 10 years, however, it controlled heartburn less well. About 39% of those patients needed acid-reducing medication, compared with 22% after a Nissen.
Partial wraps, with or without a device, are often offered to avoid the dysphagia that can follow a Nissen. In my view, that misses the point. The solution for dysphagia after a Nissen fundoplication is not a partial fundoplication of any sort. The solution is a properly performed Nissen fundoplication by an expert acid reflux specialist.
RefluxStop™ starts with a very similar partial wrap. So the obvious question is what the silicone ball adds. To answer it, a study would need to compare RefluxStop™ with the same partial fundoplication without the ball. That study has never been done.
The early RefluxStop™ results look better than what the Australian trials found with an anterior wrap alone. If those results hold up, the ball may be adding something. But the patients, the follow-up, and the study designs are all different. Only a head-to-head comparison can settle it.
The Real Test: TLESRs
Most reflux is not caused by a weak sphincter. It is caused by transient LES relaxations, or TLESRs. These are brief reflex relaxations of the LES, triggered when the upper stomach stretches after a meal. A fundoplication reduces how often they happen. That is one of the main reasons it works.
In my view, the ultimate proof of whether RefluxStop™ works is its effect on TLESRs. After eight years of experience in Europe, that still has not been studied. The published reports measure symptoms, acid exposure, endoscopy findings, and device position on x-ray. None of them report manometry data on TLESRs.
What the Evidence Shows So Far
The main prospective study enrolled 50 patients at four European centers. It had no comparison group. It excluded patients with hiatal hernias over 3 cm, severe esophagitis, a BMI over 35, or prior stomach surgery.
Within that selected group, the results were good. At 6 months, 98% had normal acid exposure on 24-hour pH testing. At 3 years, none of the 47 patients followed needed daily acid-reducing medication. Dysphagia and gas bloating were uncommon.
These are encouraging numbers. But they come from a small, carefully selected group without a control arm. They cannot show whether the ball, the partial fundoplication, or patient selection explains the outcome.
A Permanent Implant
RefluxStop™ leaves a silicone device inside the abdomen for life. In the 50-patient study, no device erosion, migration, or removal was reported. That is reassuring, but a study that size cannot rule out rare problems.
The device is built from five segments joined by an absorbable suture. According to the study authors, this design has a purpose. If the device ever works its way into the stomach, it can come apart and pass through the gut. That design shows the developers considered the possibility.
A Device to Sell, or True Value?
It is fair to ask whether RefluxStop™ was developed to sell a device or to solve a real problem. The honest answer is that no one can say yet. The operation contains a partial fundoplication, which has decades of proven value. What the silicone ball adds on top of that remains unproven.
Two studies would go a long way toward an answer. The first would compare RefluxStop™ with the same partial fundoplication without the device. The second would measure TLESRs with manometry before and after surgery.
Even if RefluxStop™ does reduce TLESRs, a more basic question remains. What advantage would it offer over a properly performed Nissen or Toupet fundoplication? Both restore the anatomy. Both reduce TLESRs. Neither leaves a permanent implant behind. In my experience at Houston Heartburn and Reflux Center, a properly performed Nissen has a dysphagia rate of zero.
What This Means If You’re Considering Reflux Surgery
A device should never be the starting point for choosing an operation. The starting point should be a clear picture of what is driving your reflux. I perform every preoperative study myself. That includes EGD, manometry, pH-impedance testing, and an upper GI contrast study. Together, they show how your LES, your esophagus, and your stomach are actually working.
From there, I choose the operation that fits your anatomy and physiology. For most patients, that is a Nissen fundoplication. When the fundus is small, a Toupet fundoplication is the better fit.
I see GERD surgery patients from across the Houston area, including Katy, Pearland, The Woodlands, and Sugar Land. Many others travel from across the country for evaluation and surgery.
Key Clinical Points
- RefluxStop™ received FDA approval in August 2026 after about eight years of use in Europe
- The manufacturer describes its mechanism in anatomic terms only: keeping the LES in the abdomen and preserving the angle of His
- The operation includes an anterior partial fundoplication covering 90 to 110 degrees of the esophagus
- The silicone ball is invaginated into the remaining fundus, reinforcing the partial fundoplication
- No study has compared RefluxStop™ with the same partial fundoplication without the device
- RefluxStop™’s effect on TLESRs, the main cause of reflux, has not been studied
- The main study enrolled 50 selected patients and had no comparison group
- The solution for dysphagia after a Nissen fundoplication is not a partial fundoplication, with or without a device, but a properly performed Nissen by an expert acid reflux specialist
- A properly performed Nissen or Toupet fundoplication restores the anatomy and reduces TLESRs without a permanent implant
If you are considering RefluxStop™ or any other reflux operation, a second opinion can help. At Houston Heartburn and Reflux Center, every evaluation starts with understanding how your reflux actually behaves. Call 832-945-8717 to schedule a consultation.
Elias F. Darido, MD, FACS
Houston Heartburn and Reflux Center
Originally published: November 2026 | Last reviewed: November 2026
References
1. FDA approves Implantica’s RefluxStop for GERD as J&J exits non-U.S. markets. MD+DI. August 25, 2026. https://www.mddionline.com/implants/fda-approves-implantica-s-refluxstop-for-gerd-as-j-j-exits-non-u-s-markets
2. Harsányi L, Kincses Z, Altorjay Á. Acid reflux management with the RefluxStop implant: a prospective multicenter trial with 3-year outcomes. Dig Dis Sci. 2025;70(2):665–674. doi:10.1007/s10620-024-08788-w
3. Hopkins RJ, Irvine T, Jamieson GG, Devitt PG, Watson DI. Long-term follow-up of two randomized trials comparing laparoscopic Nissen 360° with anterior 90° partial fundoplication. Br J Surg. 2020;107(1):56–63. doi:10.1002/bjs.11327
4. Bjelović M, Harsányi L, Altorjay Á, Kincses Z, Forsell P, et al. Non-active implantable device treating acid reflux with a new dynamic treatment approach: 1-year results. BMC Surg. 2020;20(1):159. doi:10.1186/s12893-020-00794-9
5. Harsányi L, Kincses Z, Zehetner J, Altorjay Á. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective multicenter study. Surg Endosc. 2024;38(10):6060–6069. doi:10.1007/s00464-024-11114-0

